A Functional Leptin System Is Essential for Sodium Tungstate Antiobesity ActionCANALS, Ignasi; CARMONA, Maria C; AMIGO, Marta et al.Endocrinology (Philadelphia). 2009, Vol 150, Num 2, pp 642-650, issn 0013-7227, 9 p.Article

Central and Peripheral MolecularTargets for Antiobesity PharmacotherapyVALENTINO, M. A; LIN, J. E; WALDMAN, S. A et al.Clinical pharmacology and therapeutics. 2010, Vol 87, Num 6, pp 652-662, issn 0009-9236, 11 p.Article

The Antiobesity Effects of Centrally Administered Neuromedin U and Neuromedin S Are Mediated Predominantly by the Neuromedin U Receptor 2 (NMUR2)PEIER, Andrea; KOSINSKI, Jennifer; COX-YORK, Kimberly et al.Endocrinology (Philadelphia). 2009, Vol 150, Num 7, pp 3101-3109, issn 0013-7227, 9 p.Article

Case series on a diversity of illicit weight-reducing agents: from the well known to the unexpectedTANG, Magdalene H. Y; CHEN, Sammy P. L; NG, Sau W et al.British journal of clinical pharmacology. 2011, Vol 71, Num 2, pp 250-253, issn 0306-5251, 4 p.Article

Antiobesity Pharmacotherapy: New Drugs and Emerging TargetsKIM, G. W; LIN, J. E; BLOMAIN, E. S et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 1, pp 53-66, issn 0009-9236, 14 p.Article

Minireview: Gut Peptides: Targets for Antiobesity Drug Development?MORAN, Timothy H; DAILEY, Megan J.Endocrinology (Philadelphia). 2009, Vol 150, Num 6, pp 2526-2530, issn 0013-7227, 5 p.Article

The utility of animal models to evaluate novel anti-obesity agentsVICKERS, Steven P; JACKSON, Helen C; CHEETHAM, Sharon C et al.British journal of pharmacology. 2011, Vol 164, Num 4, pp 1248-1262, issn 0007-1188, 15 p.Article

The anti-obesity effects of green tea in human intervention and basic molecular studiesHUANG, J; WANG, Y; XIE, Z et al.European journal of clinical nutrition. 2014, Vol 68, Num 10, pp 1075-1087, issn 0954-3007, 13 p.Article

Pharmacotherapy for childhood obesity: present and future prospectsSHERAFAT-KAZEMZADEH, R; YANOVSKI, S. Z; YANOVSKI, J. A et al.International journal of obesity. 2013, Vol 37, Num 1, pp 1-15, issn 0307-0565, 15 p.Article

The regulation of food intake by the gut-brain axis: implications for obesityHUSSAIN, S. S; BLOOM, S. R.International journal of obesity. 2013, Vol 37, Num 5, pp 625-633, issn 0307-0565, 9 p.Article

A comparative study of five centrally acting drugs on the pharmacological treatment of obesitySUPLICY, H; BOGUSZEWSKI, C. L; DOS SANTOS, C. M. C et al.International journal of obesity. 2014, Vol 38, Num 8, pp 1097-1103, issn 0307-0565, 7 p.Article

Partially purified Peucedanum japonicum Thunb extracts exert anti-obesity effects in vitroNUGARA, Ruwani N; INAFUKU, Masashi; IWASAKI, Hironori et al.Nutrition (Burbank, Los Angeles County, Calif.). 2014, Vol 30, Num 5, pp 575-583, issn 0899-9007, 9 p.Article

Orlistat-Induced Bullous Leukocytoclastic VasculitisLAZIC, Tamara; FONDER, Margaret; ROBINSON-BOSTOM, Leslie et al.Cutis (New York, NY). 2013, Vol 91, Num 3, pp 148-149, issn 0011-4162, 2 p.Article

Mechanism of the anti-obesity effects induced by a novel Melanin-concentrating hormone 1-receptor antagonist in miceITO, Masahiko; ISHIHARA, A; TAKENAGA, N et al.British journal of pharmacology. 2010, Vol 159, Num 2, pp 374-383, issn 0007-1188, 10 p.Article

New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier?KENNETT, G. A; CLIFTON, P. G.Pharmacology, biochemistry and behavior. 2010, Vol 97, Num 1, pp 63-83, issn 0091-3057, 21 p.Article

RIMONABANT, ADMINISTRATION ORALE (ACOMPLIA®)Journal de pharmacie de Belgique. 2008, Vol 63, Num 1, pp 27-28, issn 0047-2166, 2 p.Article

Nutrition, Obésité = Nutrition, obesity and drug interactionsLa Revue Prescrire. 2007, Vol 27, Num 290, pp 131-134, issn 0247-7750, 4 p., SUPArticle

En bref : Exénatide pour la perte de poids = In brief : exenatide for weight lossThe Medical letter on drugs and therapeutics (Edition française). 2006, Vol 28, Num 8, pp 35-35, issn 0253-8512, 1 p.Article

Tolerability and Safety of the New Anti-Obesity MedicationsHAINER, Vojtech; ALDHOON-HAINEROVA, Irena.Drug safety. 2014, Vol 37, Num 9, pp 693-702, issn 0114-5916, 10 p.Article

Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: Possible contribution of 11 β-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissueTAGAWA, Noriko; MINAMITANI, Erika; YAMAGUCHI, Yuko et al.Steroids. 2011, Vol 76, Num 14, pp 1546-1553, issn 0039-128X, 8 p.Article

Orlistat for Overweight Subjects with Nonalcoholic Steatohepatitis : A Randomized, Prospective TrialHARRISON, Stephen A; FECHT, Will; BRUNT, Elizabeth M et al.Hepatology (Baltimore, Md.). 2009, Vol 49, Num 1, pp 80-86, issn 0270-9139, 7 p.Article

Antiobesity and antidiabetic effects of biotransformed blueberry juice in KKA^y miceVUONG, T; BENHADDOU-ANDALOUSSI, A; BRAULT, A et al.International journal of obesity. 2009, Vol 33, Num 10, pp 1166-1173, issn 0307-0565, 8 p.Article

Probiotics: Interaction with gut microbiome and antiobesity potentialARORA, Tulika; SINGH, Satvinder; RAJ KUMAR SHARMA et al.Nutrition (Burbank, Los Angeles County, Calif.). 2013, Vol 29, Num 4, pp 591-596, issn 0899-9007, 6 p.Article

Safety of drug therapies used for weight loss and treatment of obesityIOANNIDES-DEMOS, Lisa L; PROIETTO, Joseph; TONKIN, Andrew M et al.Drug safety. 2006, Vol 29, Num 4, pp 277-302, issn 0114-5916, 26 p.Article

Novel Approaches to the Pharmacotherapy of Obesity : Diabetes, Obesity and Vascular Disease - An UpdateGOUNI-BERTHOLD, Ioanna; BRÜNING, Jens C; BERTHOLD, Heiner K et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 27, pp 4938-4952, issn 1381-6128, 15 p.Article